The immunosuppressive microenvironment is a major obstacle for successful tumor immunotherapy.[35] To further validate tumor cell‐intrinsic mechanisms for enhancing ICT agent responsiveness, we explored tumor immune cell profiles including T cells, DCs, Tregs and MDSCs in mice treated with RA or anti‐PD‐L1. This evidence concerns the gene CD274 and neoplasm.